Dopaminergic agonists induce anorexigenic effects, while treatment with dopamine D2 receptor [D2R] antagonists (neuroleptics) induces obesity [4]. This evidence concerns the gene DRD2 and obesity due to melanocortin 4 receptor deficiency.